GO
Loading...

Celgene Corp

More

  • Final Glance: Biotechnology companies Tuesday, 27 Jan 2015 | 6:08 PM ET

    Amgen Inc. fell$. 84 or. 5 percent, to $158.89. Biogen Idec fell $4.55 or 1.3 percent, to $357.89. Celgene Corp. fell $1.76 or 1.4 percent, to $122.36.

  • Midday Glance: Biotechnology companies Tuesday, 27 Jan 2015 | 1:36 PM ET

    Amgen Inc. fell$. 17 or. 1 percent, to $159.57. Biogen Idec fell $2.29 or. 6 percent, to $360.15. Celgene Corp. fell$. 81 or. 7 percent, to $123.31.

  • Early Glance: Biotechnology companies Tuesday, 27 Jan 2015 | 10:25 AM ET

    Amgen Inc. fell$. 82 or. 5 percent, to $158.91. Biogen Idec rose$. 02 or percent, to $362.46. Celgene Corp. fell$. 68 or. 5 percent, to $123.44.

  • Final Glance: Biotechnology companies Monday, 26 Jan 2015 | 6:04 PM ET

    Amgen Inc. fell$. 08 or. 1 percent, to $159.73. Biogen Idec rose $4.91 or 1.4 percent, to $362.44. Celgene Corp. rose$. 23 or. 2 percent, to $124.12.

  • Midday Glance: Biotechnology companies Monday, 26 Jan 2015 | 1:53 PM ET

    Amgen Inc. rose$. 26 or. 2 percent, to $160.07. Biogen Idec rose $3.25 or. 9 percent, to $360.78. Celgene Corp. rose$. 16 or. 1 percent, to $124.05.

  • Early Glance: Biotechnology companies Monday, 26 Jan 2015 | 12:16 PM ET

    Amgen Inc. fell$. 98 or. 6 percent, to $158.83. Biogen Idec fell$. 29 or. 1 percent, to $357.24. Celgene Corp. fell$. 56 or. 5 percent, to $123.33.

  • NEW YORK, Jan 26- A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells are proving to be immensely effective weapons against tumors, potentially transforming the $100 billion global market for drugs that fight the disease. But top oncology researchers are concerned about the two emerging technologies, citing...

  • Final Glance: Biotechnology companies Friday, 23 Jan 2015 | 6:04 PM ET

    Amgen Inc. rose$. 24 or. 2 percent, to $159.81. Biogen Idec rose $3.88 or 1.1 percent, to $357.53. Celgene Corp. rose$. 18 or. 1 percent, to $123.89.

  • Midday Glance: Biotechnology companies Friday, 23 Jan 2015 | 1:31 PM ET

    Amgen Inc. fell$. 45 or. 3 percent, to $159.12. Biogen Idec rose $4.60 or 1.3 percent, to $358.25. Celgene Corp. rose$. 04 or percent, to $123.75.

  • Early Glance: Biotechnology companies Friday, 23 Jan 2015 | 11:24 AM ET

    Amgen Inc. fell$. 51 or. 3 percent, to $159.07. Biogen Idec rose $2.25 or. 6 percent, to $355.90. Celgene Corp. fell$. 73 or. 6 percent, to $122.98.

  • Final Glance: Biotechnology companies Thursday, 22 Jan 2015 | 6:05 PM ET

    Amgen Inc. rose $2.19 or 1.4 percent, to $159.57. Biogen Idec fell $8.18 or 2.3 percent, to $353.65. Celgene Corp. rose $1.49 or 1.2 percent, to $123.71.

  • Midday Glance: Biotechnology companies Thursday, 22 Jan 2015 | 1:29 PM ET

    Amgen Inc. rose$. 42 or. 3 percent, to $157.80. Biogen Idec fell $10.37 or 2.9 percent, to $351.46. Celgene Corp. fell$. 20 or. 2 percent, to $122.02.

  • Early Glance: Biotechnology companies Thursday, 22 Jan 2015 | 12:09 PM ET

    Amgen Inc. fell $2.08 or 1.3 percent, to $155.30. Biogen Idec fell $10.44 or 2.9 percent, to $351.39. Celgene Corp. fell $1.14 or. 9 percent, to $121.08.

  • Final Glance: Biotechnology companies Wednesday, 21 Jan 2015 | 6:01 PM ET

    Amgen Inc. fell$. 22 or. 1 percent, to $157.38. Biogen Idec fell $1.46 or. 4 percent, to $361.83. Celgene Corp. fell $1.03 or. 8 percent, to $122.22.

  • Midday Glance: Biotechnology companies Wednesday, 21 Jan 2015 | 1:22 PM ET

    Amgen Inc. rose$. 05 or percent, to $157.65. Biogen Idec rose$. 13 or percent, to $363.41. Celgene Corp. fell$. 83 or. 7 percent, to $122.42.

  • Early Glance: Biotechnology companies Wednesday, 21 Jan 2015 | 10:45 AM ET

    Amgen Inc. fell$. 68 or. 4 percent, to $156.93. Biogen Idec fell $2.04 or. 6 percent, to $361.24. Celgene Corp. fell$. 82 or. 7 percent, to $122.43.

  • Final Glance: Biotechnology companies Tuesday, 20 Jan 2015 | 6:35 PM ET

    Amgen Inc. fell$. 83 or. 5 percent, to $157.60. Biogen Idec rose $10.53 or 3.0 percent, to $363.28. Celgene Corp. rose $1.44 or 1.2 percent, to $123.25.

  • Midday Glance: Biotechnology companies Tuesday, 20 Jan 2015 | 1:33 PM ET

    Amgen Inc. fell $2.21 or 1.4 percent, to $156.22. Biogen Idec rose $3.65 or 1.0 percent, to $356.40. Celgene Corp. fell$. 30 or. 2 percent, to $121.51.

  • Early Glance: Biotechnology companies Tuesday, 20 Jan 2015 | 10:33 AM ET

    Amgen Inc. fell $2.17 or 1.4 percent, to $156.26. Biogen Idec fell $1.29 or. 4 percent, to $351.46. Celgene Corp. fell$. 73 or. 6 percent, to $121.08.

  • TRENTON, N.J.— Celgene's new immune disorder drug, Otezla, has been approved in Europe for treating both psoriasis and a related type of arthritis, the company said Friday. Otezla, known chemically as apremilast, is the first new pill approved for psoriasis patients in 20 years and for patients with psoriatic arthritis in the last 15 years, according to Celgene...